Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Due to COVID-19 some cystic fibrosis (CF) clinical trials may be still be temporarily paused, however some trials will begin to re-open soon. If you have any questions about taking part in clinical trials, please speak to our CF team or contact the Trust’s clinical trial team. Please also see the relevant advice on the COVID-19 Q&A page. The Trials Tracker brings together all CF trials currently recruiting in the UK, so you can find clinical trials you can take part in both in your region and further afield




Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

21-25 of 64 results for all trials

Sort by:

Filter by

Therapeutic category

Trial status

A Study of CFTR modulator combination therapy for people Heterozygous for the F508del Mutation and a Minimal Function Mutation (VX-659)

A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Phase III
  • Trial Reference Number

    105982

  • Mutation

    One copy of F508del

  • Length of participation

    24 weeks

  • Trial status

    Closed

  • Therapeutic category

    Restore CFTR Function

A study looking at the long term treatment of a CFTR modulator (VX-661) when taken with Ivacaftor

This is a Phase 3, OpenLabel, Rollover study to look at how safe and effective longterm treatment with VX-661 together with Ivacaftor is in paticipants aged 12 years and older with cystic fibrosis (CF) that have a F508de-lCFTR mutation. The study involves treating all participants who meet all the rules of the study from one of the parent studies (VX-661-106,108,109 or 111) with a combination of VX-661 and Ivacaftor for approximately 96 weeks with a follow-up 28 days after the last dose. Approximately 1375 participants are potentially eligible to be enrolled. There is also an observational cohort (group) that will enable participants under 18 years of age that received at least 4 weeks of the study drug in the parent study who meet the other rules of the study to enroll. These participants will not receive any study drug but they will have regularly scheduled telephone calls to assess post treatment safety of the combination of VX661/Ivacaftor.

Read more Phase III
  • Trial Reference Number

    38799

  • Length of participation

    96 weeks (24 months)

  • Trial status

    Closed

  • Therapeutic category

    Restore CFTR Function

Observational study of outcomes in cystic fibrosis patients with selected gating mutations

The study is being done to learn more about the effectiveness of Kalydeco in CF patients with the following specific gene mutaions: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D. The study also looks to explore the effect of Kalydeco on your quality of life. This is an observational study. This means that your cystic fibrosis treatment and medical care will not change because you are participating in this study and the sponsor will not pay for Kalydeco. Your doctor will continue to make all decisions regarding your proper treatment and care. No part of this study is experimental.

Read more Phase IV
  • Trial Reference Number

    45686

  • Mutation

    No copies of F508del

  • Age

    0 - 12

  • Length of participation

    48 months (4 year)

  • Trial status

    Closed

  • Therapeutic category

    Other

A Study looking at the long-term use of a CFTR modulator (Ivacaftor) in children with cystic fibrosis who are less than 24 months and have a CFTR gating mutation

This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation

Read more Phase III
  • Trial Reference Number

    105223

  • Length of participation

    104 weeks

  • Trial status

    Closed

  • Therapeutic category

    Restore CFTR Function

A Study of CFTR modulator combinations in Subjects with Cystic Fibrosis (VX-121)

The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis.

Phase II
  • Trial Reference Number

    113399

  • Age

    18+

  • Trial status

    Completed

  • Therapeutic category

    Restore CFTR Function

21-25 of 64 results for all trials